ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OM vs JNJ // EV/EBITDA & P/E VALUATION

Outset Medical Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: OM 0 — JNJ 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OM VS. JNJ) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OM JNJ SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 39.10% 67.90% -28.80 JNJ /gross-margins <GO>
Return on Invested Capital (ROIC) -28.00% 25.50% -53.50 JNJ /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 18.5x — TIE /valuation <GO>
Free Cash Flow Yield — 2.97% — TIE /fcf-yield <GO>
Operating Margin -55.80% 34.70% -90.50 JNJ /operating-margins <GO>
Net Profit Margin -60.00% 28.50% -88.50 JNJ /net-margins <GO>
Revenue Growth (YoY) 5.10% 6.00% -0.90 JNJ /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.59 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 8/9 -2.00 JNJ /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 51.8 62.1 -10.31 JNJ /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 1.08 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 23.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $78.8M $662.49B -$662.41B JNJ /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OM REV JNJ REV OM GROSS % JNJ GROSS % OM FCF JNJ FCF
FY 2025 $119.5M $94.19B 39.1% 67.9% -$47.1M $19.70B
FY 2024 $113.7M $88.82B 33.9% 69.1% -$117.2M $19.84B
FY 2023 $130.4M $85.16B — — -$131.4M $18.96B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OM // BETA —
JNJ // BETA 1.08